🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

28 recruiting trials

for Borderline Resectable Pancreatic Adenocarcinoma

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma NCT04998552NA1 site📍 Pennington Capital Health System, Inc · Tests: Cyberknife DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer NCT07705919Phase 1, Phase 21 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fluorouracil, Gadoli… Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC NCT06714604Phase 31 site📍 Gothenburg Sahlgrenska University Hospital · Tests: FOLFIRINOX or gemcitabine-nab-paclitaxel, FOLFIRINOX or gemcitabine-nab-paclitaxel Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) NCT06384560Phase 1, Phase 24 sites📍 Amsterdam📍 Maastricht📍 Nieuwegein Amsterdam UMC, location VUmc · Tests: Pembrolizumab, Folfirinox, SABR Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment NCT06574620NA1 site📍 Vancouver British Columbia Cancer Agency · Tests: Genetic testing, Optional biopsy, Tissue collection Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma NCT05688215Phase 1, Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biospecimen Collection, Computed Tomography, Core Biopsy, Fluorouracil, Irinotecan Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas NCT02598349Phase 24 sites📍 Little Rock📍 Jacksonville📍 Warrenville Proton Collaborative Group · Tests: Proton Radiation, Capecitabine, Surgical resection Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery NCT04452461Phase 21 site📍 Hamilton Hamilton Health Sciences Corporation · Tests: mFOLFIRINOX, Gemcitabine / Nab-paclitaxel Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer NCT07645651Phase 11 site📍 Seattle University of Washington · Tests: Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy, Biospecimen Collection Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer NCT06423326Phase 22 sites📍 Washington D.C.📍 Atlanta Georgetown University · Tests: Biopsy, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma NCT05083247Phase 210 sites📍 Antwerp📍 Brussels📍 Brussels Erasme University Hospital · Tests: mFOLFIRINOX or Gemcitabine nab-paclitaxel, Isotoxic High-Dose (iHD)-SBRT, Surgery Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma NCT05825066Phase 22 sites📍 Charlotte📍 Winston-Salem Wake Forest University Health Sciences · Tests: Nab paclitaxel, Gemcitabine, Radiological Assessments, mFOLFIRINOX PULSAR in Systemic Therapy for Pancreatic Cancer NCT07269626Phase 21 site📍 Seoul Samsung Medical Center · Tests: Personalized Ultrafractionated Adaptive Radiotherapy Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer NCT05356039n/a1 site📍 Umeå Umeå University 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC NCT07043270Phase 21 site📍 Lebanon Dartmouth-Hitchcock Medical Center · Tests: Nab-paclitaxel + Gemcitabine, modified FOLFIRINOX (mFOLFIRINOX) Targeted Pathway Inhibition in Patients With Pancreatic Cancer NCT04005690EARLY Phase 11 site📍 Portland OHSU Knight Cancer Institute · Tests: Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas) NCT06024824Phase 1, Phase 22 sites📍 Dublin📍 Dublin Cancer Trials Ireland · Tests: Dose-Painted Intensity Modulated Radiotherapy Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy NCT06595160n/a1 site📍 Atlanta Emory University · Tests: Non-Interventional Study HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation NCT07240766Phase 22 sites📍 Hangzhou📍 Hangzhou Zhejiang University · Tests: HRS-4642+AG+Nimotuzumab Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma NCT05241249Phase 21 site📍 New York Susan E. Bates · Tests: Bethanechol, Gemcitabine, nab-paclitaxel AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma NCT06320717n/a2 sites📍 Buffalo📍 West Islip Roswell Park Cancer Institute · Tests: Blood sample AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer NCT07619313Phase 11 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biopsy Procedure, Cisplatin, Computed Tomography, Durvalumab, Fluorouracil A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer NCT07671339Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: ELI-002 7P, Tislelizumab, mFOLFIRINOX PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) NCT06673017Phase 19 sites📍 Newport Beach📍 Miami📍 Detroit PanTher Therapeutics · Tests: PTM-101 A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer NCT07080021n/a2 sites📍 Shanghai📍 Shanghai Ruijin Hospital · Tests: Standard Reagents, Pancreatic Cancer A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) NCT05851924Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: NALIRIFOX, AD-XRT and Capecitabine Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma NCT06141031Phase 12 sites📍 Aurora📍 St Louis Washington University School of Medicine · Tests: TTI-101, Stereotactic body radiation therapy NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial NCT06821997Phase 21 site📍 Buffalo Roswell Park Cancer Institute · Tests: Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Sucrosofate, Leucovorin Calcium
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy